Detail akcie Novo Nordisk Depository Receipt diskuze

Ahoj, tak jsem přistoupil do vláčku.

alespon jedna dobrá zpráva, FDA prý zasekl tu kopii pilule od HIM

jinak si nedokazu vysvetlit kdo prodava z ptf blizko historickych minim masinu na penize s dividendovym pomer kolem 5%, stejne tak kymebrly clark, a dalsich 50 titulu uz mam v ptf - vsechny maji neco unikatniho stabilniho, cash flow a zisk, zadne dluhy, a vetsnou PE na urovni 2-15 a nektere eps po techto poklesch jsou na urovni ze to skoro budi az uzas

Feb 4 (Reuters) - Novo Nordisk said ?on Wednesday ?it will launch ?some doses of its oral semaglutide for ?diabetes ?under the brand name ?Ozempic pill in the second quarter ?of this ?year. The company said the U.S. Food and Drug Administration has ?approved Ozempic ?tablets ?in 1.5 milligram, 4 milligram, ?and ?9 milligram doses.

The company also said it will start a new stock buyback worth as much as 15 billion Danish kroner ($2.4 billion).

Phase 3 REIMAGINE 2 data showing CagriSema achieved superior HbA1c reduction and weight loss versus semaglutide in type 2 diabetes

Novo Nordisk reported a 6% increase in sales for 2025, driven by obesity and diabetes care. However, the company expects a -5% to -13% decline in adjusted sales growth for 2026 due to competitive pressures and pricing challenges.

tak snad už dají ve výhledu náznak kolik nese ta superuspěšná pilulka

A není náhodou NOVO dánská firma? Aby jí Trump nepotopil...

Novo Nordisk A/S (NVO) stock surged over 7% in premarket trading on Tuesday, December 23, 2025, following a landmark regulatory approval from the U.S. Food and Drug Administration. The FDA greenlit the company’s oral Wegovy weight-loss pill, marking the first-ever oral GLP-1 receptor agonist therapy approved for weight management in the United States. This breakthrough gives the Danish pharmaceutical giant a significant competitive advantage over its primary rival, Eli Lilly, in the rapidly expanding obesity treatment market. The approval comes after a challenging year for Novo Nordisk, during which the stock has declined 44% year-to-date due to profit warnings and slowing sales of its injectable Wegovy formulation.

Novo Nordisk A/S shares plunged nearly 10% in premarket trading on Monday, November 24, 2025, after the Danish pharmaceutical giant announced that its phase 3 clinical trials for an Alzheimer’s disease treatment failed to meet primary endpoints. The stock dropped to $43.01 in premarket trading at 6:53 AM EST, down $4.64 or 9.73% from the previous close of $47.63.

A tady to spadlo o 10% kvůli trumpetovi a jeho hrozbě 100% cel na dovezená farmaka?

https://finance.yahoo.com/news/viking-therapeutics-stock-falls-37-122929903.html

https://finance.yahoo.com/news/health-canada-approves-ozempic-reduce-110100933.html

Myslím, že nebudeš litovat. Po schválení tablet Wegovy a následném uvedení do prodeje jako prvního takového léku očekávám prudký růst.

https://finance.yahoo.com/news/novo-nordisk-wegovy-approved-us-212300114.html

https://finance.yahoo.com/news/novo-nordisk-trading-novo-nordisk-122600499.html